Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astria Therapeutics, Inc. - Common Stock
(NQ:
ATXS
)
5.360
+0.200 (+3.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astria Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting
June 05, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
May 31, 2023
From
Astria Therapeutics
Via
Business Wire
Astria Therapeutics: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
Earnings Outlook For Astria Therapeutics
March 21, 2023
Via
Benzinga
Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
May 11, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop
April 28, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Names Andrea Matthews Chief Business Officer
April 19, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
March 28, 2023
Via
Benzinga
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
March 22, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd
March 08, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference
March 06, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
February 24, 2023
From
Astria Therapeutics
Via
Business Wire
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
February 21, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE
February 08, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
December 22, 2022
U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
$10 Million Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
December 22, 2022
Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades.
Via
Benzinga
Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 19, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
December 19, 2022
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5. Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on...
Via
Benzinga
Dow Dips Over 800 Points; S&P 500 Down 2.8%
December 15, 2022
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 800 points.
Via
Benzinga
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session
December 15, 2022
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Via
Benzinga
RCI Hospitality, AbCellera Biologics And Some Other Big Stocks Moving Higher On Thursday
December 15, 2022
U.S. stocks traded lower, with the Dow Jones dropping over 600 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Astria Therapeutics' Potential Hereditary Angioedema Candidate Shows Encouraging Action In Healthy Participants
December 15, 2022
Via
Benzinga
Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
December 15, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
December 15, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.